ALTHOUGH stroke is one of the leading causes of death and disability, T&T lacks a national stroke registry. This means we do ...

A newly developed drug has been found to offer 24 hour protection from high blood pressure, including early mornings when the ...

The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

CHRISTUS Health is expanding neurological care to treat strokes and aneurysms in San Antonio's Westover Hills community.

OCEAN was an open-label trial conducted in Australia, Belgium, Canada, China, Germany, and Israel. Eligible participants had ...

The results have potential to change clinical practice.NEW ORLEANS — Left atrial appendage closure in patients with atrial ...

For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications may not be sufficient in helping them reach their target cholesterol levels.

In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients ...